What Causes LDL Particle Number to Be Out of Range?: A Functional-Medicine Interpretation Guide

Why LDL Particle Number Matters More Than LDL Cholesterol

For decades, standard lipid panels measured LDL cholesterol concentration — the amount of cholesterol carried inside LDL particles. But a growing body of cardiovascular research has established that LDL particle number (LDL-P) is a far stronger predictor of atherosclerotic risk than LDL-C alone.

The MESA (Multi-Ethnic Study of Atherosclerosis) trial, which followed over 5,600 adults, found that LDL-P predicted cardiovascular events independently of LDL-C, and that discordance between the two markers was common — meaning many people with "normal" LDL cholesterol still carried a high-risk LDL particle burden (Cromwell et al., Journal of the American College of Cardiology 2007; PMID: 17239460).

The mechanism is straightforward: it is the LDL particle itself — not the cholesterol it carries — that penetrates the arterial wall and initiates plaque formation. A person with many small, dense LDL particles carries a higher number of atherogenic projectiles even if total cholesterol looks acceptable.

Optimal vs. Reference Ranges for LDL-P

Because each LDL particle carries one ApoB molecule, ApoB is often used as a surrogate for LDL-P when NMR testing isn't available. Elevated ApoB with normal LDL-C is a classic sign of discordance that warrants a deeper metabolic investigation.

---

What Causes LDL to Be Out of Range? The Particle-Level View

When clinicians ask what causes LDL to be out of range, the answer diverges sharply depending on whether you're looking at LDL-C or LDL-P. Several distinct physiological pathways can drive LDL particle number upward.

1. Overproduction of VLDL in the liver

The liver continuously packages triglycerides and cholesterol into very-low-density lipoprotein (VLDL) particles. As VLDL circulates and offloads triglycerides, it shrinks into intermediate-density lipoprotein and then into LDL. When VLDL production is chronically elevated — driven by excess dietary carbohydrates, fructose, or hepatic fat accumulation — more LDL particles are generated downstream.

2. Impaired LDL receptor clearance

The liver normally recycles LDL via LDL receptors. Saturated fat intake, familial hypercholesterolemia gene variants (LDLR, PCSK9 gain-of-function mutations), and hypothyroidism all downregulate LDL receptor activity, allowing LDL-P to accumulate in circulation.

3. CETP-mediated particle remodeling

Cholesterol Ester Transfer Protein (CETP) exchanges triglycerides from VLDL for cholesterol in LDL. In a hypertriglyceridemic state, this exchange produces cholesterol-depleted, triglyceride-enriched LDL particles — which hepatic lipase then hydrolyzes into the small, dense LDL subfractions most associated with plaque progression (Packard & Shepherd, Arteriosclerosis, Thrombosis, and Vascular Biology 1997; PMID: 9409259).

4. Chronic inflammation

Inflammation shifts lipoprotein metabolism toward atherogenic phenotypes. Elevated C-reactive protein (hs-CRP), interleukin-6, and TNF-α all alter hepatic lipid handling, increase VLDL secretion, and impair reverse cholesterol transport.

Understanding these four pathways is essential because they point to entirely different interventions — and they all converge on the metabolic drivers discussed below.

---

What Causes Fasting Insulin to Be Out of Range? The LDL-P Connection

If there is one upstream driver that single-handedly explains a significant proportion of elevated LDL particle number, it is insulin resistance. Fasting insulin is one of the earliest markers to move out of optimal range — often years before blood glucose or A1C shifts.

Functional-medicine optimal fasting insulin sits between 2–5 µIU/mL. Conventional lab references often extend to 25 µIU/mL or higher — a threshold that would miss early-stage insulin resistance entirely.

The link between fasting insulin and LDL-P operates through several mechanisms:

• Hepatic VLDL overproduction: Insulin normally suppresses VLDL secretion from the liver. In insulin-resistant hepatocytes, this inhibitory signal fails, and the liver floods the bloodstream with VLDL particles. Each of these ultimately becomes an LDL particle.
• Small dense LDL shift: Insulin resistance elevates postprandial triglycerides, which fuels the CETP exchange reaction described above, shifting the LDL pool toward the more atherogenic small-dense subfraction.
• Reduced LDL receptor expression: Hyperinsulinemia paradoxically downregulates hepatic LDL clearance in the context of insulin-resistant signaling.

A landmark analysis from the Framingham Heart Study Offspring cohort confirmed that insulin resistance — assessed via HOMA-IR — was independently associated with elevated LDL particle number and small LDL-P concentrations, even after adjusting for LDL-C (Garvey et al., Diabetes 2003; PMID: 12540640).

This is why a clinician who sees elevated LDL-P on a patient's NMR panel should immediately look at fasting insulin and HOMA-IR before defaulting to a statin prescription. If insulin resistance is the driver, addressing it directly — through dietary carbohydrate reduction, resistance exercise, and targeted supplementation — can lower LDL-P significantly without pharmacological intervention.

For a broader look at how insulin resistance affects cardiovascular biomarkers, the metabolic connections run deeper than most standard labs reveal.

---

What Causes Fasting Glucose to Be Out of Range? Glycemic Dysregulation and Lipoproteins

Fasting glucose is a lagging indicator — it rises only after significant insulin resistance has already developed. Still, when fasting glucose climbs above 90 mg/dL (the functional-medicine threshold, versus the conventional 100 mg/dL cutoff for impaired fasting glucose), it reflects a metabolic environment that is actively worsening lipoprotein profiles.

Functional-Medicine Reference Ranges for Fasting Glucose:

Elevated fasting glucose contributes to LDL particle dysregulation through glycation of ApoB. When glucose is persistently elevated, ApoB proteins become glycated — a modification that reduces their recognition by hepatic LDL receptors, extending LDL particle residence time in the bloodstream and increasing atherogenic exposure (Lyons 1991; doi.org/10.1016/0021-9150(91)90219-D).

Furthermore, hyperglycemia generates advanced glycation end-products (AGEs) that promote oxidative stress and endothelial dysfunction — creating an arterial environment where even modestly elevated LDL-P causes disproportionate damage.

Patients with fasting glucose in the 95–110 mg/dL range often display the classic triad of metabolic dyslipidemia: elevated triglycerides, low HDL, and high LDL particle number — despite apparently normal LDL-C. This pattern, sometimes called atherogenic dyslipidemia, represents one of the most clinically important yet underdiagnosed phenotypes in functional medicine.

To learn how fasting glucose connects to cardiovascular risk scoring, tracking it alongside LDL-P gives a far more complete metabolic picture.

---

What Causes A1C to Be Out of Range? Long-Term Glycemic Burden on Lipoproteins

Hemoglobin A1C reflects average blood glucose over approximately 90 days. While most clinicians use it primarily as a diabetes management tool, A1C is also a sensitive indicator of cumulative glycemic burden on the lipoprotein system.

Functional-Medicine A1C Targets:

A large meta-analysis in Diabetologia found that each 1% increase in A1C was associated with a significant increase in cardiovascular event risk, independent of other traditional risk factors (Selvin et al., Annals of Internal Medicine 2004; PMID: 15520422). This risk is substantially mediated through the lipoprotein changes described above — specifically elevated LDL-P, glycated ApoB, and small-dense LDL predominance.

One underappreciated point: A1C can be falsely low in people with rapid red blood cell turnover (hemolytic anemia, iron deficiency) or falsely high in those with slow red blood cell turnover. Fructosamine or continuous glucose monitoring can provide complementary glycemic assessment when A1C seems discordant with clinical presentation.

For patients working to understand how A1C trends predict metabolic disease progression, combining this marker with fasting insulin and LDL-P creates a much richer diagnostic picture than any single test alone.

---

Other Root Causes That Drive LDL-P Out of Range

Beyond glycemic and insulin-related pathways, several additional drivers are worth screening when LDL particle number is elevated:

• Hypothyroidism: Thyroid hormone upregulates hepatic LDL receptor expression. Subclinical hypothyroidism (TSH 2.5–4.5 mIU/L with symptoms) is frequently associated with elevated LDL-P.
• Dietary patterns: High intake of saturated fat, trans fats, and refined carbohydrates each have distinct mechanistic effects on LDL receptor downregulation and VLDL production.
• Gut dysbiosis: Short-chain fatty acids produced by a healthy microbiome support bile acid synthesis and cholesterol excretion. Dysbiosis reduces this pathway.
• Genetic variants: APOE ε4 carriers have impaired LDL clearance; familial hypercholesterolemia affects roughly 1 in 250 people and requires specialized management.
• Sedentary lifestyle: Exercise upregulates LDL receptor expression and improves insulin sensitivity, both of which lower LDL-P.
• Chronic psychological stress: Cortisol dysregulation — especially elevated evening cortisol — impairs insulin sensitivity and elevates LDL-P indirectly.

---

What This Means for Your Formula

When Ones analyzes your lab results alongside wearable data and health history, elevated LDL particle number doesn't trigger a generic response — it prompts a root-cause investigation of the metabolic pathways outlined above. Here are three clinically relevant ingredients that may appear in a Ones formula when LDL-P and its upstream drivers are out of range:

Omega-3 (EPA/DHA) — Omega-3 fatty acids at doses of 2–4 g/day have demonstrated statistically significant reductions in VLDL triglycerides (and therefore downstream LDL-P) in randomized controlled trials. The REDUCE-IT trial (Bhatt et al., New England Journal of Medicine 2019; PMID: 30415628), using 4 g/day of icosapentaenoic acid, showed a 25% relative reduction in major cardiovascular events in patients with elevated triglycerides. Ones includes a clinically dosed EPA/DHA combination calibrated to your triglyceride status.

Ones Heart Support (System Blend) — This proprietary blend is formulated to address multiple cardiovascular risk pathways simultaneously — including endothelial function, oxidative modification of LDL, and lipid metabolism. It complements individual actives when the cardiovascular picture is multifactorial, which is common when LDL-P elevation tracks alongside glycemic dysregulation.

Berberine (where applicable) — Berberine activates AMPK, improves insulin sensitivity, and has demonstrated LDL-lowering effects in several randomized trials. A meta-analysis of 27 trials found berberine significantly reduced LDL-C, triglycerides, and fasting glucose (Dong et al., Evidence-Based Complementary and Alternative Medicine 2012; PMID: 23118706). When fasting insulin and glucose are simultaneously out of range alongside elevated LDL-P, an AI-guided formula from Ones may incorporate berberine as a metabolic anchor.

Because Ones formulas come in structured 6- or 9-capsule daily plans — the configuration selected by the AI based on your specific findings — every ingredient included displaces something else. The platform's strength is prioritization: identifying which three or four drivers are most responsible for your LDL-P elevation and addressing those with clinical precision, rather than carpet-bombing with a dozen marginally effective supplements.

If you're curious how NMR lipid panel results are interpreted for personalized supplement formulas, the methodology goes beyond LDL-C into particle size distribution, ApoB, and metabolic context.

---

Key Takeaways

• LDL particle number (LDL-P) is a stronger predictor of cardiovascular risk than LDL cholesterol — many people with "normal" LDL-C have dangerously elevated LDL-P.
• Insulin resistance is the most common upstream driver of elevated LDL-P; fasting insulin (optimal: 2–5 µIU/mL) should always be checked alongside a lipid panel.
• Fasting glucose above 90 mg/dL and A1C above 5.4% signal glycemic stress that glycates ApoB proteins and impairs LDL receptor clearance — compounding particle-level risk.
• VLDL overproduction, CETP-mediated particle remodeling, impaired LDL receptor activity, and chronic inflammation are four distinct mechanistic pathways that can each independently drive LDL-P out of range.
• Root-cause investigation — including thyroid function, gut health, genetics, stress biomarkers, and dietary pattern — is essential before attributing elevated LDL-P to a single cause.
• Targeted interventions — including Omega-3 fatty acids, berberine, and lifestyle modification — address LDL-P at the mechanism level; platforms like Ones use lab and wearable data to build formulas calibrated to your specific metabolic profile.

This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your supplement or medication regimen.